New Promising Weight Loss Research!
Viking Therapeutics Reports Promising Preclinical Data On Dual GLP-1/GIP Agonists.
What Is This Buzz All About?
Viking Therapeutics, well known from LGD-4033 or VK5211, presented promising preclinical data on novel dual GLP-1/GIP agonists at ObesityWeek 2021.
The company’s dual-receptor agonists demonstrate potent weight loss and improvement of metabolic profile in diet-induced obese mice.
Therefore they plan to start the first clinical trials in humans in the upcoming months.
Rat’s Army is happy to give you all the details about this preclinical research!
But What Does That Mean?
GLP-1 And GIP
Glucagon-like peptide-1 (GLP-1) is a 30 or 31 amino acid long peptide hormone deriving from the tissue-specific posttranslational processing of the proglucagon peptide.
So it is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption.
Consequently, alongside glucose-dependent insulinotropic peptide (GIP), GLP-1 is an incretin.
Thus, it has the ability to decrease blood sugar levels in a glucose-dependent manner by enhancing the secretion of insulin.
Besides the insulinotropic effects, GLP-1 has been associated with numerous regulatory and protective effects.
Unlike GIP, the action of GLP-1 is preserved in patients with type 2 diabetes and substantial pharmaceutical research has therefore been directed towards the development of GLP-1-based treatment.
So to put it simply these peptides make sure the body functions properly in digesting foods in an efficient way.
So Viking Therapeutics has been experimenting with their own internally developed dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
And the results from the preclinical data were very promising.
So we will give you a small overview:
- Novel Co-Agonists of GLP-1 and GIP Receptors Produce Robust Weight Loss in a Rodent Model of Obesity.
- 21-day study comparing a series of novel GLP-1/GIP dual agonists to vehicle and to the GLP-1 agonist semaglutide.
- Treatment with Viking dual agonists resulted in mean reductions in body weight of up to 27% relative to vehicle compared with a mean reduction of 18% among semaglutide-treated animals.
- Treatment with Viking dual agonists resulted in mean reductions in blood glucose of up to 23% relative to vehicle compared with a mean reduction of 7% among semaglutide-treated animals.
- As well treatment with Viking dual agonists resulted in mean reductions in plasma insulin of up to 57% relative to vehicle compared with a mean reduction of 35% among semaglutide-treated animals.
- Novel Dual Incretin Receptor Agonists Reduce Body Weight and Improve Metabolic Profile in DIO Mice.
- 14-day study comparing a series of novel GLP-1/GIP dual agonists to vehicle and to the GLP-1/GIP dual agonist tirzepatide.
- Treatment with Viking dual agonists resulted in mean reductions in body weight of up to 28%and reductions in plasma glucose of up to 26%.
These effects were comparable to those observed among tirzepatide-treated animals.
- Treatment with Viking dual agonists resulted in mean reductions in plasma triglycerides of up to 37% relative to vehicle compared with a 29% mean reduction among tirzepatide-treated animals.
- As well treatment with Viking dual agonists resulted in mean reductions in liver triglycerides of up to 49% relative to vehicle compared with a 19% mean reduction among tirzepatide-treated animals.
At Viking Therapeutics, researchers are very excited about these results.
These new dual agonists result from our internal development activities focused on important therapeutic targets and represent an expansion of our pipeline of novel agents for metabolic and endocrine disorders.
Furthermore, the results of these and other preclinical studies provide the rationale for Viking’s continued advancement of its internal dual GLP-1/GIP agonist development program.
Therefore they plan to initiate a first-in-human Phase 1 trial with a lead candidate in the upcoming months.
Viking Therapeutics (LGD-4033 or VK5211) presented promising results with research on dual GLP-1/GIP agonists.
In brief, these peptides regulate metabolic rate, insulin sensitivity, and the ability to digest and store food in the body.
The results from the research gave some exciting perspectives for weight loss research.
In the end, both researched agonists they developed in-house produced reduction in weight loss, blood glucose levels, plasma insulin, cholesterol levels…
So this means these agonists will be perfect for any weight loss research and to fix metabolic and endocrine disorders.
OTHER NEWS FLASH:
So starting on December 13th the Christmas Sale is live until December 26th.
Read all about it here!